Rare CFH Variants in PNH Patients

At a median follow-up of 5.8 years, eight out of nine patients harboring CFH variants had received transfusions and two developed thromboses. Development of aplastic anemia or progression to myeloid malignancy were not associated with either common or rare complement gene variants. Study authors concluded that these findings show for the first time that rare CFH variants are overrepresented among PNH patients.